Jotul Holdings SA - Interim financial report for the half-year ended 30. June 2021
30 août 2021 10h00 HE
|
Jøtul AS
In the first half of 2021, the Jotul Group reached a consolidated loss of MNOK 54.1 (H1 2020: loss of MNOK 68.5). The operating loss totaled MNOK 1.2 in H1 2021 (H1 2020: loss of MNOK 60.1). The 2021...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport, 1 januari – 30 juni 2021
13 août 2021 02h00 HE
|
Infant Bacterial Therapeutics AB
VD kommenterar Som bekant genomför IBT en stor fas III-studie (“The Connection Study”) vilket är den sista studien i vårt kliniska utvecklingsprogram med läkemedelskandidaten IBP-9414, som...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2021
13 août 2021 02h00 HE
|
Infant Bacterial Therapeutics AB
Message from the CEO As is well known, IBT is conducting a large phase III study ("The Connection Study"), the final study in our clinical development program with our drug candidate IBP-9414,...
Jotul Holdings SA - Financial report for the period from 1 January to 31 March 2021
28 mai 2021 07h00 HE
|
Jøtul AS
YTD Q1 2021, the Jotul Group reached a consolidated profit of MNOK -10.1 (Q1 2020: MNOK -25.3). The operating result totaled MNOK 7.3 in YTD Q1 2021 (Q1 2020: MNOK -45,2). The total comprehensive...
Jotul Holdings SA - Annual report and the report of the Réviseur d’Entreprises Agréé for the year ended 31 December 2020
21 mai 2021 12h16 HE
|
Jøtul AS
The revenue in 2020 declined by 6.1%, to MNOK 905.5 compared to MNOK 961.1 in 2019. The decline is less than initially anticipated at the outbreak of the COVID-19 pandemic in March 2020. In the...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 mars 2021
04 mai 2021 02h00 HE
|
Infant Bacterial Therapeutics AB
VD kommenterar Som bekant genomför vi en fas III-studie (“The Connection Study”) vilket är den sista fasen av vårt kliniska utvecklingsprogram med läkemedelskandidaten IBP-9414 som innehåller...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2021
04 mai 2021 02h00 HE
|
Infant Bacterial Therapeutics AB
Message from the CEO IBT is conducting a phase III-study (“The Connection Study”) which is the last phase of the clinical development program with the pharmaceutical candidate IBP-9414 containing...
Jotul Holdings SA – Delayed publication of audited consolidated annual financial statements
30 avr. 2021 06h00 HE
|
Jøtul AS
Jotul Holdings SA (the "Company") publication of its audited consolidated financial statements for the financial year ended 31 December 2020 (the "Financial Statements") which were to be published and...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 december 2020
05 févr. 2021 02h00 HE
|
Infant Bacterial Therapeutics AB
VD Kommenterar IBT utvecklar läkemedelskandidaten IBP-9414 för att förebygga nekrotiserande enterokolit (”NEC”), samt förbättra så kallad “feeding tolerance” hos för tidigt födda barn....
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2020
05 févr. 2021 02h00 HE
|
Infant Bacterial Therapeutics AB
Message from the CEO IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so-called "feeding tolerance" in premature infants....